Neurocognitive Function After Therapy of OSAS
Launched by UNIVERSITY OF ERLANGEN-NÜRNBERG MEDICAL SCHOOL · Jul 20, 2015
Trial Information
Current as of July 09, 2025
Completed
Keywords
ClinConnect Summary
Obstructive Sleep Apnea Syndrome (OSAS) is characterized by repeated episodes of airway obstruction while sleeping. The "Apnea-hypopnea index" (AHI) defined as events per hour, gives information about the severity of the disease. The American Academy of Sleep Medicine Task Force" defined that more than 5 episodes per hour is strongly suspect for an OSAS disease. Upper airway obstruction while sleeping leads to a dramatic decrease in oxygen saturation and to hypoxemia finally, in which consequence the patient rapidly awake. The prevalence rise with age and about 20% of the population is susp...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \* Patients within 30 to 70 years of age both gender.
- Exclusion Criteria:
- • Patients under 30 years of age or older than 70 years of age.
- • Preexisting neurological, neuropsychological deficits or diseases, e.g. cerebral insult or epilepsy.
- • Preexisting neurological, neuropsychological medication.
- • Preexisting neuromuscular diseases.
- • Alcohol - and drug abuse.
- • Postoperative complications, pain and time shifts within the test protocol.
About University Of Erlangen Nürnberg Medical School
The University of Erlangen-Nürnberg Medical School is a prestigious institution dedicated to advancing medical research and improving healthcare outcomes through innovative clinical trials. Renowned for its interdisciplinary approach, the medical school fosters collaboration among experts in various fields, enabling the development of cutting-edge therapies and treatment protocols. With a commitment to ethical standards and patient safety, the institution actively contributes to the global medical community by conducting rigorous clinical studies aimed at enhancing the understanding and management of diverse health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Erlangen, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials